checkAd

     194  0 Kommentare 22nd Century Group Regulatory Science VP Joins FDLI Tobacco and Nicotine Products Committee - Seite 3

    About 22nd Century Group, Inc.
    22nd Century Group, Inc. (NYSE American: XXII) is a leading plant biotechnology company focused on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp/cannabis plants through genetic engineering, gene-editing, and modern plant breeding. 22nd Century’s primary mission in tobacco is to reduce the harm caused by smoking through the Company’s proprietary reduced nicotine content tobacco cigarettes – containing 95% less nicotine than conventional cigarettes. The Company’s primary mission in hemp/cannabis is to develop and commercialize proprietary hemp/cannabis plants with valuable cannabinoid profiles and desirable agronomic traits.

    Learn more at xxiicentury.com, on Twitter @_xxiicentury, and on LinkedIn.

    Cautionary Note Regarding Forward-Looking Statements
    Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 11, 2021. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

    Investor Relations & Media Contact:
    Mei Kuo
    Director, Communications & Investor Relations
    22nd Century Group, Inc.
    (716) 300-1221
    mkuo@xxiicentury.com


    Seite 3 von 3



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    22nd Century Group Regulatory Science VP Joins FDLI Tobacco and Nicotine Products Committee - Seite 3 Another key indicator and milestone of the Increasing Importance of Reducing Cigarette Nicotine Content as Cornerstone of Public Health PolicyBUFFALO, N.Y., April 08, 2021 (GLOBE NEWSWIRE) - 22nd Century Group, Inc. (NYSE American: XXII), a …